Keith Manchester's most recent trade in Roivant Sciences Ltd was a trade of 6,837,266 Common Shares done . Disclosure was reported to the exchange on June 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 25 Jun 2025 | 6,837,266 | 0 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 25 Jun 2025 | 6,205,368 | 8,441,428 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 25 Jun 2025 | 3,176,245 | 19,347,727 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 25 Jun 2025 | 1,170,646 | 1,592,480 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 11.63 per share. | 24 Sep 2024 | 368,052 | 1,412,126 | - | 11.6 | 4,278,605 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 11.77 per share. | 24 Sep 2024 | 134,948 | 1,277,178 | - | 11.8 | 1,587,704 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 27,894 | 27,894 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Sep 2024 | 16,406 | 1,780,178 | - | 0 | Common Shares | |
| Arbutus Biopharma Corp | Keith Manchester | Director | 14 Aug 2024 | 54,915 | 0 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | Keith Manchester | Director | 14 Aug 2024 | 54,915 | 54,915 (0%) | 0% | 0.6 | 30,752 | Common Shares | |
| Arbutus Biopharma Corp | Keith Manchester | Director | 14 Aug 2024 | 8,846 | 46,069 (0%) | 0% | 3.7 | 32,637 | Common Shares | |
| Arbutus Biopharma Corp | Keith Manchester | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 07 Mar 2024 | 11,325,233 | 23,105,358 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 07 Mar 2024 | 11,077,765 | 14,646,796 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 07 Mar 2024 | 5,594,064 | 6,837,266 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 07 Mar 2024 | 2,260,661 | 2,763,126 | - | 0 | Common Shares | |
| Arbutus Biopharma Corp | Keith Manchester | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 09 Nov 2022 | 2,311,643 | 28,010,344 | - | 4.7 | 10,980,304 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Other type of transaction at price $ 0.00 per share. | 09 Nov 2022 | 1,196,200 | 38,582,314 | - | - | Common Shares | |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 09 Nov 2022 | 1,092,355 | 37,489,959 | - | 4.7 | 5,188,686 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 09 Nov 2022 | 372,427 | 13,535,929 | - | 4.7 | 1,769,028 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 09 Nov 2022 | 146,079 | 5,470,181 | - | 4.7 | 693,875 | Common Shares |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 71,850 | 71,850 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Keith Manchester | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 52,142 | 52,142 | - | 0 | Common Shares | |
| Arbutus Biopharma Corp | Keith Manchester | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | Keith Manchester | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options |